Tempus AI, Inc. (TEM)
Automate Your Wheel Strategy on TEM
With Tiblio's Option Bot, you can configure your own wheel strategy including TEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEM
- Rev/Share 4.7114
- Book/Share 1.9131
- PB 29.5804
- Debt/Equity 2.6296
- CurrentRatio 1.7059
- ROIC -0.5453
- MktCap 9511219946.0
- FreeCF/Share -1.2473
- PFCF -44.7216
- PE -13.6072
- Debt/Assets 0.5558
- DivYield 0
- ROE -5.3065
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEM | BTIG Research | -- | Buy | -- | $60 | April 21, 2025 |
| Downgrade | TEM | JP Morgan | Overweight | Neutral | $50 | $55 | Feb. 25, 2025 |
| Downgrade | TEM | William Blair | Outperform | Market Perform | -- | -- | Feb. 12, 2025 |
| Resumed | TEM | TD Cowen | -- | Buy | $58 | $74 | Feb. 5, 2025 |
| Initiation | TEM | Wolfe Research | -- | Outperform | -- | $60 | Dec. 13, 2024 |
| Initiation | TEM | Guggenheim | -- | Buy | -- | $74 | Dec. 9, 2024 |
| Downgrade | TEM | BofA Securities | Buy | Neutral | $45 | $60 | Oct. 2, 2024 |
News
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos
Published: April 23, 2025 by: Proactive Investors
Sentiment: Positive
Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model in oncology, sending its shares up more than 15% in morning trading. The deals, which include $200 million in data licensing and model development fees to Tempus, will leverage the company's vast repository of de-identified oncology data and artificial intelligence capabilities to help identify new drug targets and advance cancer therapies.
Read More
Why Tempus AI Stock Is Skyrocketing Today
Published: April 23, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Tempus AI (TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday.
Read More
Why Quantum Computing (QUBT), Nano Nuclear Energy (NNE) and Tempus AI (TEM) Are Popping Higher Today
Published: April 22, 2025 by: 24/7 Wall Street
Sentiment: Positive
Analysts at BTIG initiated coverage of TEM with a buy rating with a price target of $60.
Read More
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
Published: April 18, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise.
Read More
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Published: April 15, 2025 by: PRNewsWire
Sentiment: Neutral
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
Read More
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.
Read More
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
Read More
Should Investors Buy Tempus AI Stock Right Now?
Published: February 28, 2025 by: The Motley Fool
Sentiment: Neutral
Tempus AI (TEM -11.18%) is utilizing artificial intelligence to deliver better healthcare outcomes.
Read More
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
Read More
Tempus AI Down 13%- Is It Time to Buy?
Published: February 25, 2025 by: 24/7 Wall Street
Sentiment: Negative
Shares of Nancy Pelosi's favorite artificial intelligence stock Tempus AI (NASDAQ:TEM) are falling more than 13% in morning trading after reporting fourth quarter and full-year 2024 earnings results yesterday after the market closed.
Read More
Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
Read More
Tempus AI, Inc. (TEM) Q4 2024 Earnings Call Transcript
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI, Inc. (NASDAQ:TEM ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Liz Krutoholow - Investor Relations Eric Lefkofsky - Founder & Chief Executive Officer Jim Rogers - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Mike Ryskin - Bank of America Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Doug Schenkel - Wolfe Research Andrew Brackmann - William Blair Mark Schappel - Loop Capital Dan Arias - Stifel David Westenberg - Piper Sandler Operator Thank you for standing by. My name is Jason, and I will be your conference …
Read More
Tempus AI Gears Up For Q4 Earnings After 101% YTD Surge
Published: February 24, 2025 by: Benzinga
Sentiment: Positive
Tempus AI Inc TEM will be reporting its fourth-quarter earnings on Monday. Wall Street expects a loss of 20 cents per share and $203.12 million in revenues as the company reports after market hours.
Read More
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Read More
5 stocks Congress is buying in 2025
Published: February 20, 2025 by: Finbold
Sentiment: Neutral
The stock trading activities of US Congress members continue to draw attention, with disclosures under the STOCK Act providing insight into their investment strategies. So, in this piece, we bring you the top 5 stocks Congress is buying in 2025.
Read More
Ares Management Upsizes Tempus Debt Facilities to $560 Million
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, Inc. (NASDAQ: TEM) (“Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care. The financing is intended to support Tempus' previously announced acquisition of Ambry Genetics (“Ambry”), whi.
Read More
Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Recently, they've made some interesting moves like acquiring Ambry Genetics, launching the Olivia health app, and collaborating with IFLI. TEM also has other innovative assets like xT CDx, xH tests, and enhanced Tempus One that I think position it perfectly for agentic AI diagnostics.
Read More
Conflicting Signals: Tempus AI's Stock Market Rally
Published: February 17, 2025 by: MarketBeat
Sentiment: Positive
Tempus AI NASDAQ: TEM is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus AI's stock price has seen an increase, with gains of over 160% in the last month and almost 150% year-to-date, causing investors to surge in interest.
Read More
AI Roundup: 3 Explosive AI-Adjacent Stocks to Watch in 2025
Published: February 11, 2025 by: Schaeffers Research
Sentiment: Positive
Artificial Intelligence (AI) has dominated headlines to start the year, especially after President Donald Trump revealed a joint venture to invest "$500 billion, at least" for AI Infrastructure in the U.S. More recently, Chinese startup DeepSeek shook up the sector after its AI model beat out OpenAi -- at a significantly lower cost.
Read More
Cathie Wood Is Betting Big on These 2 AI Stocks
Published: February 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Cathie Wood's comeback could continue through the year as most of her Ark Invest funds come roaring back alongside the tech trade.
Read More
About Tempus AI, Inc. (TEM)
- IPO Date 2024-06-14
- Website https://www.tempus.com
- Industry Medical - Healthcare Information Services
- CEO Eric P. Lefkofsky
- Employees 2400